Back to Investors
Oxford Sciences Innovation

Oxford Sciences Innovation

Venture Capital

Oxford Sciences Innovation is a science business builder that works with academics to commercialise research and build companies based on Oxford science.

Portfolio

11

companies

AUM

£600M

under management


Portfolio companies

Ultromics

Ultromics

Ultromics develops artificial intelligence software for automated cardiovascular imaging and diagnostics.

Orbit Discovery

Orbit Discovery

Orbit Discovery develops proprietary screening platforms for candidate peptide therapeutics.

OC

Omega Crop

Omega Crop builds remote-sensing and modelling technology to help farms predict yields and diagnose crop losses.

Oxford Endovascular

Oxford Endovascular

Oxford Endovascular develops origami engineered medical devices to prevent brain haemorrhage.

Mind Foundry

Mind Foundry

Mind Foundry develops artificial intelligence platforms designed to help organisations make better operational decisions.

ORCA Computing

ORCA Computing

ORCA Computing develops full-stack photonic quantum computing systems.

PQShield

PQShield

PQShield builds quantum-resistant cryptographic solutions for the global technology supply chain.

Mixergy

Mixergy

Mixergy develops smart hot water tanks that reduce energy usage and emissions.

Y

YASA

YASA manufactures axial flux electric motors and controllers for electric vehicles.

MT

MoA Technology

MoA Technology develops next-generation herbicides to combat global weed resistance.

Z

Zegami

Zegami provides visual data exploration software that helps businesses unlock insights from complex datasets.


Team

Charles Conn

Charles Conn

CEO

Charles brings investment, executive, and board experience from roles including CEO of Oxford Sciences Innovation, co-founder of Monograph Capital, and chair of Patagonia.

LinkedIn
MF

Martin Fiennes

Principal

WG

Will Goodlad

Principal

ND

Nick Dixon-Clegg

Principal

Matt Arnold

Matt Arnold

Principal

Matt brings financial and investment experience from roles at Mind Foundry, Oxford Science Enterprises, and Goldman Sachs. He serves as chief financial officer at Fractile.


Recent investments

Series B
£23.7M

The Series B round was led by the Blue Venture Fund to accelerate the deployment of artificial intelligence in echocardiography.

"Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy,"
— Ross Upton, CEO and co-founder
Seed
£5.6M

The financing round was led by Oxford Sciences Innovation to support the company in expanding its peptide discovery operations.

"Orbit’s team has the right combination of scientific rigor and novel peptide technologies to lead a new generation of drug development, and we look forward to partnering with the team to advance their mission,"
— Nick Dixon-Clegg, Principal
Seed
£1.2M

Oxford Sciences Innovation led the seed investment, which will fund commercialisation and technological advancement.

"The world must create 70% more food by 2050 in a sustainable way. We need to double production, improve efficiencies on existing farmland, and avoid destroying more rainforests. At Omega Crop we can monitor and evaluate vast tracts of farmland, diagnosing crop loss events at scale and enable targeted interventions that will help feed our growing world."
— Jared Bainbridge, CEO
Series A
£7.3M

The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.

"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
— Mike Karim, CEO
Series A
£10.4M

The University of Oxford spinout secured £10.4m from backers including Parkwalk Advisors and Oxford Sciences Innovation to expand its presence in the insurance sector.

"There are some technologies that can change a small part of the insurance value chain, but there are no technology companies that can help insurers transform the entire insurance operation. Therefore, we had been seeking a reliable partner with first-class technology in order to jointly develop such solutions across the insurance value chain."
— Satoru Tamura, Senior Managing Executive Officer
Series B
£3.6M

The financing round was led by Foresight Williams Technology to support product rollout and grid balancing services.

"This round comes at an exciting time in markets across the UK, Western Europe and North America. With recent pledges to transition from natural gas in new build properties by 2025 across Europe along with unprecedented volatility in the UK’s electricity balancing market, Mixergy is well positioned to accelerate the low carbon transition through relationships with low cost manufacturing supply chains that cater to a global market."
— Peter Armstrong, CEO
Series D+
£18.0M

The funding round was led by Parkwalk Advisors, Universal Partners, Oxford Sciences Innovation and Inovia Capital to support customer demand and company growth.

"We have been tracking YASA’s progress for a number of years and are pleased to have the opportunity to invest in one of the UK’s most exciting high-growth technology companies that is well positioned to take advantage of the rapid move to electrification in both automotive and aerospace sectors."
— Charles Conn, CEO
Series A
£6.3M

The Oxford-based crop protection firm secured the financing from co-leads Oxford Sciences Innovation and Parkwalk Advisors.

"Weeds are now a greater threat to crop yields than at any time in recent decades. New solutions are urgently needed. Raising £6m at this stage in the company’s development is a real testament to the strength of the company’s prospects."
— Hadyn Parry, Chairman
Seed
£1.3M

The financing round was led by RT Capital Management alongside the Oxford Technology and Innovations EIS Fund.

"Over the last few years Zegami has been developing a cutting edge Visual Data Exploration platform to democratise data analytics, enabling people to make sense of the tsunami of data available today."
— Samuel Conway, Co-Founder and CEO